Share “News Summary: Pfizer rheumatoid arthritis...”

News Summary: Pfizer rheumatoid arthritis drug

Associated Press Modified: November 6, 2012 at 5:19 pm •  Published: November 6, 2012
Advertisement

APPROVAL: Pfizer Inc. says the Food and Drug Administration approved its rheumatoid arthritis drug Xeljanz, a twice-per-day pill.

WHO IT'S FOR: Xeljanz is designed to slow the progression of moderate to severe rheumatoid arthritis. It is approved for patients who either cannot take methotrexate, a standard treatment for the disease, or haven't been helped by it. Xeljanz interferes with enzymes that contribute to tissue inflammation.

THE BIG PICTURE: Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will likely take the drugs regularly for a long time.


AROUND THE WEB

  1. 1
    Son and five others indicted on murder charges in Pryor woman's overdose death
  2. 2
    Du'Vonta Lampkin released by Texas, eligible for OU football
  3. 3
    Shocker: Keith Richards doesn't like rap
  4. 4
    Black Sabbath Announce Final Tour 'The End'
  5. 5
    Trump expected to sign Republican loyalty pledge: party official
+ show more

FEATURED JOBS



× Trending business Article